[[PAGE:1]]

FREQUENTLY ASKED QUESTIONS

What is the approved starting dose for the authorised product? 80 mg once daily in first-line metastatic EGFR-positive NSCLC within EU label boundaries.

[[PAGE:2]]

MISSED DOSE

Patient-facing answers must use only approved missed-dose guidance and avoid improvised rescue instructions; advise clinician follow-up when uncertain.